FrancophonIA/ELRC3.0 huggingface dataset:
English: Elderly In the pivotal phase III study, ExteNET (3004), the mean age was 52 years in the Nerlynx arm,
Croatian: U ključnom ispitivanju faze III, ExteNET (3004), učestalost štetnih događaja nastalih tijekom liječenja
English: An HDPE desiccant canister with 1 g silica gel is enclosed with the tablets in each bottle.
Croatian: U svakoj se bočici s tabletama nalazi spremnik od HDPE-a s 1 g silika gela.
English: 1 vs. 4
Croatian: 1 u odnosu na 4
English: 200 mg daily
Croatian: 200 mg dnevno
English: Variable
Croatian: OBLIK
English: Each film coated tablet contains neratinib maleate equivalent to 40 mg neratinib.
Croatian: Jedna filmom obložena tableta sadrži neratinibmaleat u količini koja odgovara 40 mg neratiniba.
English: • Permanently discontinue Nerlynx treatment
Croatian: • Trajno prekinuti liječenje lijekom Nerlynx
English: Distant disease-free survival Time to distant recurrence CNS recurrence
Croatian: Razdoblje do recidiva bolesti na udaljenom mjestu
English: Very common: may affect more than 1 in 10 people - diarrhoea - stomach pain, feeling or being sick, low appetite - dry or inflamed mouth, including blisters or mouth ulcers - rash - muscle spasms or cramps - feeling very tired
Croatian: - bol u trbuhu, osjećaj mučnine ili povraćanje, smanjeni apetit - suha ili upaljena usta, uključujući mjehuriće ili ulkuse u ustima
English: Co-administration with proton pump inhibitors (PPIs) and H2-receptor antagonists is not recommended.
Croatian: Ne preporučuje se istodobna primjena s inhibitorima protonske pumpe (PPI) i antagonistima
English: 26 vs. 55
Croatian: 26 u odnosu na
English: 7 vs. 20
Croatian: 7 u odnosu na
English: • Grade 3 diarrhoea lasting between 2 days and 3 weeks‡
Croatian: • Proljev 3. stupnja koji traje između
English: What Nerlynx is and what it is used for 2.
Croatian: Što je Nerlynx i za što se koristi
English: Uncommon: may affect up to 1 in 100 people - kidney failure - changes in liver blood test results (i.e., blood bilirubin increased)
Croatian: - promjene u rezultatima krvnih pretraga jetrene funkcije (tj. povećanje bilirubina u krvi)
English: P-value3
Croatian: Pvrijednost3
English: • Permanently discontinue Nerlynx • Evaluate alternative causes
Croatian: • Ocijeniti alternativne uzroke
English: • If diarrhoea resolves to Grade 0-1 in one week or less, then resume Nerlynx treatment at the same dose.
Croatian: • Potrebno je održavati unos tekućine od ~2 l kako bi se izbjegla dehidracija • Ako se težina proljeva smanji na 0.-1. stupanj u roku od tjedan dana ili manje, nastaviti liječenje lijekom Nerlynx u istoj dozi.
English: Following concomitant administration with repeated doses of 600 mg rifampicin, a strong CYP3A4/Pgp inducer, neratinib exposures were significantly decreased with mean values that were 24% and 13% of reference values (neratinib administered alone) for Cmax and AUC, respectively.
Croatian: izloženosti neratinibu značajno su smanjene; srednje vrijednosti iznosile su 24 % i 13 % referentnih vrijednosti (neratinib primijenjen samostalno) za Cmax, odnosno AUC.
English: Talk to your doctor before taking Nerlynx if you are breast-feeding or plan to breast-feed because small amounts of this medicine may pass into your breast milk.
Croatian: Budući da se male količine ovog lijeka mogu izlučiti u Vaše mlijeko, ako dojite ili planirate dojiti razgovarajte sa svojim liječnikom prije uzimanja lijeka Nerlynx.
English: o The Summary of Product Characteristics o Guide for healthcare professionals o Patient educational material The Guide for healthcare professionals shall contain the following key elements: o Name of the product, active substance and approved indication of the product o Relevant information on the safety concern “Gastrointestinal toxicity (diarrhoea)” (e.g. seriousness, severity, frequency, time to onset, duration, reversibility of the AE as applicable) o Details of the population at higher risk for the safety concern o Key message to convey in patients counselling on how to prevent and minimise Gastrointestinal toxicity through appropriate monitoring and management: o prophylactic treatment with antidiarrhoeal medicinal product o dietary changes o dose modification (with guideline to adjust doses)/ discontinuation of treatment o The importance of handing over the educational material to the patients/carers at the end of counselling o Remarks on the importance of reporting ADRs
Croatian: o profilaktičko liječenje lijekom protiv proljeva o promjene u prehrani o prilagodba doze (sa smjernicama za prilagodbu doza)/prekid liječenja o Važnost davanja edukacijskog materijala bolesnicima/njegovateljima na kraju savjetovanja o Napomene o važnosti prijavljivanja nuspojava lijeka
English: 19 vs. 35
Croatian: 19 u odnosu na
English: OR
Croatian: o
English: The most common TEAEs in the Skin SOC that occurred more frequently in Asian patients than in Caucasian patients were rash (29.4% vs. 13.5%), Palmar-plantar erythrodysaesthesia syndrome (9.9% vs. 1.0%), and dermatitis acneiform (6.0 vs. 1.0%).
Croatian: 13,5 %), palmarno-plantarna eritrodisestezija (9,9 % u odnosu na 1,0 %) i akneiformni dermatitis (6,0 u odnosu na 1,0 %).
English: 3 Includes nail disorder, paronychia, onychoclasis, and nail discolouration.
Croatian: 3 Obuhvaća poremećaj noktiju, paronihiju, onihoklaziju i promjenu boje na površini nokta.
English: The serious adverse reactions most frequently reported in the ≥65 years-old group were vomiting (2.3%), diarrhoea (1.7%), dehydration (1.2%), and renal failure (1.2%).
Croatian: (2,3 %), proljev (1,7 %), dehidracija (1,2 %) i zatajenje bubrega (1,2 %).
English: Missed dose
Croatian: Nuspojava lijeka
English: Grade 3 adverse reactions were reported in 1.6% vs 0.5% and Grade 4 adverse reactions were reported in 0.2% vs. 0.1%, Nerlynx- and placebo-treated patients, respectively.
Croatian: Nuspojave 3. stupnja prijavljene su u 1,6 % bolesnika liječenih lijekom Nerlynx u odnosu na 0,5 % bolesnika koji su primali placebo, a nuspojave 4. stupnja prijavljene su u 0,2 % odnosno 0,1 % bolesnika.
English: Grade 3 AST increased was reported in 0.5% vs 0.3% and Grade 4 AST increased was reported in 0.2% vs 0.0%, of Nerlynx- vs placebo-treated patients.
Croatian: Povišena aspartat aminotransferaza 3. stupnja prijavljena je u 0,5 % bolesnika koji su primali lijek Nerlynx u odnosu na 0,3 % bolesnika koji su primali placebo, a povišena aspartat aminotransferaza 4. stupnja prijavljena je u 0,2 % bolesnika koji su primali Nerlynx u odnosu na 0,0 % bolesnika koji su primali placebo.
English: - The active substance is neratinib.
Croatian: - Djelatna tvar je neratinib.
English: 9 vs. 28
Croatian: 9 u odnosu na
English: Fatigue, dizziness, dehydration, and syncope have been reported as adverse reactions with neratinib.
Croatian: Kao nuspojave kod uzimanja neratiniba prijavljeni su umor, omaglica, dehidracija i sinkopa.
English: Treatment of patients with Child-Pugh C hepatic impairment is not recommended (see Section 5.2).
Croatian: Ne preporučuje se liječenje bolesnika s teškim oštećenjem funkcije jetre (Child Pugh C)
English: • If grade 3 diarrhoea persists longer than 3weeks, discontinue Nerlynx permanently.
Croatian: • Ako proljev 3. stupnja potraje dulje od 3 tjedna,
English: You need to take an anti-diarrhoea medicine when you start Nerlynx
Croatian: Kada započnete liječenje lijekom Nerlynx, morate uzeti lijek protiv proljeva
English: Grade 3 ALT increased was reported in 1.1% vs 0.2% and Grade 4 ALT increased was reported in 0.2% vs 0.0% of Nerlynx- vs placebotreated patients.
Croatian: Povišena alanin aminotransferaza 3. stupnja prijavljena je u 1,1 % bolesnika liječenih lijekom Nerlynx u odnosu na 0,2 % bolesnika koji su primali placebo, a povišena alanin aminotransferaza 4. stupnja prijavljena je u 0,2 % bolesnika liječenih lijekom Nerlynx u odnosu na 0,0 % bolesnika koji su primali placebo.
English: No. of Patients
Croatian: Broj bolesnica
English: Breast-feeding
Croatian: Krospovidon
English: Mannitol (E421) Microcrystalline cellulose Crospovidone Povidone
Croatian: Jezgra tablete Manitol (E421)
English: Common: may affect up to 1 in 10 people - burning sensation during urination and frequent, and urgent need to urinate, (may be symptoms of urinary tract infection) - dehydration - nosebleed - mild stomach upset - dry mouth - changes in liver blood test results - nail problems including nail splitting or colour change - dry skin including cracked skin - changes in kidney function test - weight loss
Croatian: - dehidracija - krvarenje iz nosa - blagi nadražaj želuca - suha usta - promjene u rezultatima krvnih pretraga jetrene funkcije
English: Concomitant treatment with substances that increase gastric pH should be avoided, as neratinib solubility and absorption may decrease.
Croatian: Budući da može doći do smanjenja topljivosti i apsorpcije neratiniba, potrebno je izbjegavati istodobnu primjenu s tvarima koje povećavaju pH vrijednost želuca.
English: Proton pump inhibitors, H2-receptor antagonists and antacids Co-administration with proton pump inhibitors (PPIs) and H2-receptor antagonists are not recommended.
Croatian: Inhibitori protonske pumpe, antagonisti H2 receptora i antacidi
English: The incidence of Grade 1 and Grade 2 was 13.3% and 2.9% respectively; 0.4% of Nerlynx-treated patients experienced Grade 3 rash.
Croatian: U skupini bolesnika liječenih samo lijekom Nerlynx 16,7 % bolesnika dobilo je osip. 13,3 % bolesnika imalo je osip 1. stupnja, a njih 2,9 % osip 2. stupnja, dok je 0,4 % bolesnika liječenih lijekom Nerlynx dobilo osip 3. stupnja.
English: Hepatic impairment
Croatian: Zatajenje bubrega
English: Hepatotoxicity
Croatian: Kancerogeneza, mutageneza
English: Package leaflet: Information for the patient Nerlynx 40 mg film-coated tablets neratinib This medicine is subject to additional monitoring.
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži neratinibmaleat u količini koja odgovara 40 mg neratiniba.
English: Nerlynx can cause diarrhoea early during treatment.
Croatian: Kada započnete liječenje lijekom Nerlynx, morate uzeti lijek protiv proljeva Nerlynx može uzrokovati proljev u ranoj fazi liječenja.
English: • Grade 1 diarrhoea [increase of < 4 stools per day over baseline]
Croatian: • Proljev 1. stupnja [povećanje od
English: CYP3A4/P-gp inhibitors
Croatian: Učinci drugih tvari na neratinib Inhibitori CYP3A4/Pgp
English: Nerlynx dose modifications for adverse reactions
Croatian: Tablica 1: Prilagodbe doze lijeka Nerlynx zbog nuspojava Razina doze
English: Severity of diarrhoea*
Croatian: Težina proljeva*
English: Discontinue Nerlynx for patients who:
Croatian: Potrebno je prekinuti liječenje lijekom Nerlynx u bolesnika:
English: Elderly
Croatian: Proljev
English: Action
Croatian: System
English: Very Common Muscle spasms
Croatian: Mikrokristalična celuloza
English: Nerlynx can cause diarrhoea early during treatment unless anti-diarrhoea medicine is taken to prevent or reduce diarrhoea.
Croatian: Ako ne uzmete lijek protiv proljeva radi sprječavanja ili smanjenja proljeva, Nerlynx može uzrokovati proljev u ranoj fazi liječenja.
English: Management of some adverse reactions may require dose interruption and/or dose reduction as shown in Table 1, Table 2, Table 3, and Table 4.
Croatian: Radi zbrinjavanja nekih nuspojava možda će biti potrebno privremeno prekinuti liječenje i/ili smanjiti dozu,
English: This summary was last updated in August-2014.
Croatian: Ovaj sažetak posljednji je put ažuriran u kolovozu-2014.
English: It is used in patients from 12 years of age and weighing at least 40 kg.
Croatian: Koristi se u bolesnika od 12 godina pa nadalje i koji teže najmanje 40 kg.
English: Data from this study collected until week 96 showed that this effect was maintained over time.
Croatian: Podaci iz ovog ispitivanja koji su prikupljeni do 96. tjedna pokazali su da je ovaj učinak održan s vremenom.
English: After 48 weeks, 88% of the patients given the combination found in Triumeq (364 out of 414) responded to treatment, compared with 81% of the patients who were given Atripla (338 out of 419).
Croatian: Nakon 48 tjedana, 88% bolesnika dobilo je kombinaciju nađenu u lijeku Triumeq (364 od 414) reagiralo je na liječenje u usporedbi s 81% bolesnika koji su primili lijek Atripla (338 od 419).
English: Data from this study had already been used in the authorisation of Tivicay.
Croatian: Podaci iz ovog ispitivanja već su korišteni u odobravanju lijeka Tivicay.
English: The full EPAR and risk management plan summary for Triumeq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije (EPAR) za lijek Triumeq, kao i Plan upravljanja rizicima možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The main measure of effectiveness was the response rate, which was the proportion of patients with a reduction of the levels of virus in the blood (viral load) to fewer than 50 copies of HIV RNA per ml.
Croatian: Glavna mjera djelotvornosti bila je stopa odgovora koja predstavlja udio bolesnika sa smanjenjem razine virusa u krvi (virusno opterećenje) na manje od 50 kopija HIV RNK po ml.
English: Before starting treatment with Triumeq, all patients should have a test to find out if they have a gene called ‘HLA-B (type 5701)'.
Croatian: Prije početka liječenja lijekom Triumeq sve bolesnike treba testirati kako bi se otkrilo imaju li gen zvani "HLA-B (tip 5701)".
English: Other information about Triumeq
Croatian: Ostale informacije o lijeku Triumeq
English: Triumeq reduces the amount of HIV in the blood and keeps it at a low level.
Croatian: Triumeq smanjuje količinu virusa HIV-a u krvi i održava je niskom.
English: The CHMP concluded that the medicine had demonstrated its effectiveness in previously untreated patients, and that similar benefits are expected in patients who have received previous treatment.
Croatian: CHMP je zaključio da je lijek dokazao svoju djelotvornost kod prethodno neliječenih bolesnika i da se slične koristi očekuju kod bolesnika koji su prethodno liječeni lijekom.
English: Why is Triumeq approved?
Croatian: Zašto je Triumeq odobren?
English: It is not intended to provide practical advice on how to use Triumeq.
Croatian: Svrha sažetka nije davati praktične savjete o načinu korištenja lijeka Triumeq.
English: What is Triumeq and what is it used for?
Croatian: Što je Triumeq i za što se koristi?
English: Triumeq is available as tablets (50 mg dolutegravir / 600 mg abacavir /300 mg lamivudine) and the recommended dose is one tablet a day, taken with or without food.
Croatian: Triumeq je dostupan u obliku tableta (50 mg dolutegravira/600 mg abakavira/300 mg lamivudina), a preporučena doza je jedna tableta dnevno s hranom ili bez nje.
English: All three active substances in Triumeq are already available in the European Union (EU) as singlecomponent medicines: abacavir has been authorised as Ziagen since 1999, lamivudine as Epivir since 1996, and dolutegravir as Tivicay since January 2014.
Croatian: Sve tri djelatne tvari u lijeku Triumeq već su dostupne u Europskoj uniji (EU) kao monokomponentni lijekovi: abakavir je odobren kao Ziagen od 1999. godine, lamivudin kao Epivir od 1996. godine, a dolutegravir kao Tivicay od siječnja 2014.
English: Triumeq dolutegravir / abacavir / lamivudine
Croatian: Triumeq dolutegravir / abakavir / lamivudin
English: Triumeq does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Croatian: Triumeq ne liječi infekciju HIV-om niti AIDS, ali može usporiti oštećenje imunološkog sustava i razvoj infekcija i bolesti povezanih s AIDSom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Triumeq on 1 September 2014.
Croatian: Europska komisija izdaje odobrenje za stavljanje u promet koje za lijek Triumeq vrijedi na prostoru Europske unije od 1. rujna 2014.
English: The combination of dolutegravir, abacavir and lamivudine (as found in Triumeq) was evaluated in one main study involving 833 previously untreated patients.
Croatian: Kombinacija dolutegravira, abakavira i lamivudina (kako je otkriveno u lijeku Triumeq) procijenjena je u jednom glavnom ispitivanju koje je uključivalo 833 prethodno neliječena bolesnika.
English: This is a summary of the European public assessment report (EPAR) for Triumeq.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Triumeq.
English: Patients with this gene are at an increased risk of having an allergic reaction to abacavir, so they should not take Triumeq.
Croatian: Bolesnici s ovim genom pod povećanim su rizikom od alergijske reakcije na abakavir tako da ne smiju uzimati Triumeq.
English: What measures are being taken to ensure the safe and effective use of Triumeq?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Triumeq?
English: The CHMP also considered the fact that Triumeq can be taken with or without food as an additional advantage compared with other similar medicines which have to be taken strictly either with food or on an empty stomach.
Croatian: CHMP je također uzeo u obzir činjenicu da se Triumeq može uzimati s hranom ili bez nje kao dodatnu prednost u usporedbi s drugim sličnim lijekovima koje treba uzimati strogo s hranom ili natašte.
English: The combination of abacavir and lamivudine has been authorised as Kivexa since 2004.
Croatian: Kombinacija abakavira i lamivudina odobrena je kao lijek Kivexa od 2004.
English: The most common side effects with Triumeq (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), headache, nausea (feeling sick), diarrhoea and fatigue (tiredness).
Croatian: Najčešće nuspojave s lijekom Triumeq (koje mogu zahvatiti više od 1 na 10 osoba) su nesanica (poteškoće sa spavanjem), glavobolja, mučnina, proljev i umor (zamor).
English: They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Croatian: Obje djeluju na isti način blokirajući aktivnost reverzne transkriptaze, enzima koji proizvodi HIV i koji omogućava virusu da zarazi stanice i da se replicira.
English: Giving the combined medicine rather than the single medicines reduces the number of tablets patients have to take, helping them to adhere to their treatment.
Croatian: S obzirom da kombinirani lijek smanjuje broj tableta koje bolesnik mora uzeti radije nego pojedinačni lijek, to pomaže bolesniku da se pridržava liječenja.
English: The CHMP also noted that giving the combination of dolutegravir, abacavir and lamivudine as a single tablet is an additional treatment option for patients with HIV infection and without the HLA-B (type 5701) gene.
Croatian: CHMP je također zabilježio da primjena kombinacije dolutegravira, abakavira i lamivudina kao pojedinačnih tableta u jednoj tableti može pružiti dodatnu opciju liječenja za bolesnike s HIV infekcijom i bez gena HLA-B (tip 5701).
English: This is an antiviral medicine that blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Croatian: To je antivirusni lijek koji blokira enzim zvan integraza koja je potrebna kako bi se virus HIV-a kopirao u nove kopije u tijelu.
English: Results from this study showed that Triumeq was absorbed into the body in the same way as the separate medicines.
Croatian: Rezultati ovog ispitivanja pokazali su da se lijek Triumeq apsorbira u tijelo na isti način kao i zasebni lijekovi.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Triumeq's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Triumeq nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Triumeq must not be used together with dofetilide, a medicine used to control cardiac arrhythmia (unstable heartbeat).
Croatian: Triumeq se ne smije koristiti zajedno s dofetilidom, lijekom koji se koristi za kontrolu srčanih aritmija (nestabilnih otkucaja srca).
English: In patients taking some of the components of Triumeq, certain serious side effects have been seen including hypersensitivity (allergic).
Croatian: Kod bolesnika koji uzimaju neke komponente lijeka Triumeq uočene su ozbiljne nuspojave uključujući preosjetljivost (alergijsku).
English: What are the risks associated with Triumeq?
Croatian: Koji su rizici povezani s lijekom Triumeq?
English: Regarding Triumeq's safety profile, this was expected to be similar to the safety profile of the single components and comparable to that of other HIV treatments.
Croatian: Što se tiče sigurnosnog profila lijeka Triumeq očekuje se da će biti sličan sigurnosnom profilu pojedinačnih komponenti i usporediv s drugim terapijama protiv HIV-a.
English: Triumeq is an antiviral medicine used to treat patients with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).
Croatian: Triumeq je antivirusni lijek koji se koristi za liječenje bolesnika s virusom humane imunodeficijencije (HIV), virusa koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
English: Patients were either given the Triumeq combination or a different three-drug combination (Atripla) that did not include an integrase inhibitor.
Croatian: Bolesnici su primali ili kombinaciju lijeka Triumeq ili različitu kombinaciju od tri lijeka (Atripla) koja nije uključivala inhibitor integraze.
English: The other two active substances, abacavir and lamivudine, are nucleoside reversetranscriptase inhibitors (NRTIs).
Croatian: Druge dvije djelatne tvari, abakavir i lamivudin inhibitori su enzima reverzne transkriptaze nukleozida (NRTI-ovi).
English: A risk management plan has been developed to ensure that Triumeq is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Triumeq.
English: In addition, the company that markets Triumeq will provide educational material for healthcare professionals expected to prescribe Triumeq that addresses the risk of abacavir-associated hypersensitivity.
Croatian: Pored toga, tvrtka koja trži lijek Triumeq osigurati će dodatni edukacijski materijal za zdravstvene djelatnike za koje se očekuje da će propisivati Triumeq, a koji obrađuju rizik od preosjetljivosti na abakavir.
English: Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.
Croatian: Triumeq sadrži tri djelatne tvari: dolutegravir, abakavir i lamivudin.
English: For more information about treatment with Triumeq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Triumeq pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: For practical information about using Triumeq, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Triumeq bolesnici trebaju pročitati u uputi o lijeku ili se obratiti svom liječniku ili ljekarniku.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Triumeq, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputi o lijeku, za lijek Triumeq uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Triumeq can only be obtained with a prescription and treatment should be prescribed by a doctor who is experienced in managing HIV infections.
Croatian: Triumeq se izdaje samo na recept, a liječenje treba propisati liječnik iskusan u dijagnozi i liječenju HIV infekcija.